An inhibitor of MMP-2, -3, -9, -13, and -14
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Prinomastat

Item No. 37699

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(3S)-N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide
CAS Number
192329-42-3
Synonyms
  • AG-3340
  • KB-R9896
Molecular Formula
C18H21N3O5S2
Formula Weight
423.5
Purity
≥95%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Soluble
λmax
229, 242 nm
SMILES
O=S(N1[C@H](C(C)(SCC1)C)C(NO)=O)(C2=CC=C(C=C2)OC3=CC=NC=C3)=O
InChi Code
InChI=1S/C18H21N3O5S2/c1-18(2)16(17(22)20-23)21(11-12-27-18)28(24,25)15-5-3-13(4-6-15)26-14-7-9-19-10-8-14/h3-10,16,23H,11-12H2,1-2H3,(H,20,22)/t16-/m0/s1
InChi Key
YKPYIPVDTNNYCN-INIZCTEOSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $33

    Add

    5 mg

    $139

    Add

    10 mg

    $261

    Add

    25 mg

    $530

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Prinomastat is an inhibitor of matrix metalloproteinase-2 (MMP-2), MMP-3, MMP-9, MMP-13, and MMP-14 (IC50s = 0.05, 0.3, 0.26, 0.03, and 0.33 nM, respectively).1 It is selective for these MMPs over MMP-1 and MMP-7 (IC50s = 8.3 and 54 nM, respectively). Prinomastat (50 mg/kg) reduces tumor growth and inhibits the formation of lung metastases in a murine Lewis lung carcinoma model. It also reduces the incidence of kidney, but not brain, metastasis and tumor microvessel density in an NCI H460 lung cancer orthotopic mouse model when administered at a dose of 100 mg/kg.2 Prinomastat reduces bronchoalveolar lavage fluid (BALF) levels of TNF-α and pulmonary edema in a rat model of ventilator-induced lung injury.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Scatena, R. Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases. Expert Opin. Investig. Drugs 9(9), 2159-2165 (2000).

    2. Liu, J., Tsao, M.S., Pagura, M., et al. Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model. Lung Cancer 42(3), 335-344 (2003).

    3. Foda, H.D., Rollo, E.E., Drews, M., et al. Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: Attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340). Am. J. Respir. Cell Mol. Biol. 25(6), 717-724 (2001).